<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227796</url>
  </required_header>
  <id_info>
    <org_study_id>LEVI-04_17_01</org_study_id>
    <nct_id>NCT03227796</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability &amp; Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Pain Attributed to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Levicept</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hammersmith Medicines Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MAC Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Levicept</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, phase 1, single centre, placebo-controlled, double-blind, single&#xD;
      ascending dose study of LEVI-04 in heathy volunteers and osteoarthritis patients (with pain&#xD;
      attributed to osteoarthritis of the knee)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 8 cohorts of 7 subjects each. Cohorts 1-3 and 8 will be composed of healthy&#xD;
      volunteers. Cohorts 4-7 will be composed of osteoarthritis patients. Cohort 4 will be a&#xD;
      bridging cohort; osteoarthritis patients in Cohort 4 will receive the same dose as the&#xD;
      healthy volunteers in Cohort 3, if deemed safe.&#xD;
&#xD;
      Each subject will be assigned to receive a single dose of LEVI-04 or matching placebo. Each&#xD;
      dose will be administered as an intravenous infusion over 30 minutes. Planned doses will&#xD;
      start at 0.003 mg/kg in Cohort 1, and may be increased to 3.0 mg/kg in Cohort 8. The planned&#xD;
      doses may be changed, depending on the safety, tolerability and pharmacokinetic results after&#xD;
      previous doses. The dose selected for each cohort will be determined by the Safety Review&#xD;
      Team, following review of all available pharmacokinetic and safety data. For each escalating&#xD;
      dose, there will be at least 2 weeks between the start of each cohort (at least 14 days&#xD;
      between Day 0 for the last subject in the previous cohort and Day 0 for the first subject in&#xD;
      the subsequent cohort), to allow for review of safety, tolerability and pharmacokinetic data.&#xD;
      In each cohort, 5 subjects will receive LEVI-04 and 2 subjects will receive matching placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2017</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>First-in-human, phase 1, placebo-controlled, double-blind, single ascending dose study in heathy volunteers and osteoarthritis patients</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events [Safety and tolerability]</measure>
    <time_frame>Change from Baseline at Day 56 post-dose for healthy volunteers and change from Baseline at Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>adverse events; laboratory tests; electrocardiograms and injection site reaction assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in neurological assessments [Safety and tolerability] - SAS</measure>
    <time_frame>Change from Baseline at Day 56 post-dose for healthy volunteers and change from Baseline at Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Neurological assessment (Survey of Autonomic Symptoms (SAS) Questionnaire)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in neurological assessments [Safety and tolerability] - BCTQ</measure>
    <time_frame>Change from Baseline at Day 56 post-dose for healthy volunteers and change from Baseline at Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Neurological assessment (Boston Carpal Tunnel Questionnaire (BCTQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in neurological assessments [Safety and tolerability] - 4th finger test</measure>
    <time_frame>Change from Baseline at Day 56 post-dose for healthy volunteers and change from Baseline at Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Neurological assessment (the carpal tunnel syndrome (CTS) 4th finger neurological test or Total Neuropathy Score nurse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - maximum concentration</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - time to maximum concentration</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Time to reach maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - Area Under the Curve</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Area under the serum concentration-time curve from time zero to time of last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - half-life</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - clearance</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Apparent total body clearance after intravenous administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - elimination rate</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single ascending intravenous doses of LEVI-04 in healthy volunteers and osteoarthritis patients - volume of distribution</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the formation of anti-drug antibodies (ADA) to LEVI-04 in healthy volunteers and osteoarthritis patients</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 post-dose for osteoarthritis patients</time_frame>
    <description>Presence / concentration of any anti-drug antibodies to LEVI-04</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics of LEVI-04 in osteoarthritis patients - pain relief (rescue medication)</measure>
    <time_frame>Up to Day 105 for osteoarthritis patients</time_frame>
    <description>Use of rescue medication, by treatment and time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics of LEVI-04 in osteoarthritis patients - pain relief (NRS-11)</measure>
    <time_frame>Up to Day 105 for osteoarthritis patients</time_frame>
    <description>Assessment of pain using the Numerical Rating Scale-11 (NRS-11) questionnaire by treatment and time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics of LEVI-04 in osteoarthritis patients - pain relief (WOMAC)</measure>
    <time_frame>Up to Day 105 for osteoarthritis patients</time_frame>
    <description>Assessment of pain using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire by treatment and time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory analyses of pharmacological biomarkers relevant to the actions of LEVI-04 in healthy volunteers and osteoarthritis patients (NGF)</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 for osteoarthritis patients</time_frame>
    <description>Measurement of total, free and LEVI-04 bound Nerve Growth Factor (NGF)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory analyses of pharmacological biomarkers relevant to the actions of LEVI-04 in healthy volunteers and osteoarthritis patients (NT-3)</measure>
    <time_frame>Up to Day 56 post-dose for healthy volunteers and up to Day 105 for osteoarthritis patients</time_frame>
    <description>Measurement of Neurotropin-3 (NT-3)</description>
  </other_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Healthy Volunteers Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Healthy Volunteers Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Healthy Volunteers Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 Healthy Volunteers Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match LEVI-04 single intravenous dose Healthy Volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEVI-04</intervention_name>
    <description>LEVI-04 intravenous infusion</description>
    <arm_group_label>Cohort 1 Healthy Volunteers Active</arm_group_label>
    <arm_group_label>Cohort 2 Healthy Volunteers Active</arm_group_label>
    <arm_group_label>Cohort 3 Healthy Volunteers Active</arm_group_label>
    <arm_group_label>Cohort 4 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_label>Cohort 5 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_label>Cohort 6 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_label>Cohort 7 Osteoarthritis Patients Active</arm_group_label>
    <arm_group_label>Cohort 8 Healthy Volunteers Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intravenous infusion</description>
    <arm_group_label>Cohort 1 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Healthy Volunteers Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_label>Cohort 5 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_label>Cohort 6 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_label>Cohort 7 Osteoarthritis Patients Placebo</arm_group_label>
    <arm_group_label>Cohort 8 Healthy Volunteers Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index 18.0-&lt;32.0 kg/m2 (healthy volunteers) and 18.0-&lt;40.0 kg/m2&#xD;
             (osteoarthritis patients)&#xD;
&#xD;
          -  Willing and able to give written fully informed consent&#xD;
&#xD;
          -  Men with female partners of childbearing potential must agree to follow the&#xD;
             requirements for effective contraception throughout the study and for 112 days&#xD;
             post-dose&#xD;
&#xD;
          -  Women of non childbearing potential&#xD;
&#xD;
          -  Healthy volunteers (aged 18 to 65 years) willing to give written consent to have data&#xD;
             entered into the Over-volunteering Prevention System&#xD;
&#xD;
          -  Osteoarthritis patients (aged 30-80 years) with diagnosis of mild to moderate&#xD;
             osteoarthritis of the knee, with X-ray confirmation as diagnosed by a trained&#xD;
             radiology reviewer&#xD;
&#xD;
          -  Osteoarthritis patients willing to discontinue all pain medication, except rescue&#xD;
             medication (paracetamol), from the run-in visit until the end of the study&#xD;
&#xD;
          -  Osteoarthritis patients with a Numerical Rating Scale-11 pain score of between 5 and&#xD;
             &lt;9, inclusive, in the index knee at screening. If taking regular pain medication,&#xD;
             should show an increase of at least 1 point following washout of analgesia. The&#xD;
             average pain score of between 5 and &lt;9, inclusive, based on four of the seven daily&#xD;
             readings during the seven day initial pain assessment period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential, or who are pregnant or lactating&#xD;
&#xD;
          -  Clinically relevant abnormal history, physical findings, electrocardiograph, or&#xD;
             laboratory values at screening that could interfere with the objectives of the trial&#xD;
             or the safety of the subject&#xD;
&#xD;
          -  Presence of acute or chronic illness or history of chronic illness (other than&#xD;
             osteoarthritis, controlled diabetes, asthma or hypertension for osteoarthritis&#xD;
             patients), sufficient to invalidate participation in the trial or make it&#xD;
             unnecessarily hazardous&#xD;
&#xD;
          -  Impaired endocrine, thyroid, hepatic, respiratory (other than asthma that has been&#xD;
             controlled by the use of acceptable medication for at least 3 months prior to&#xD;
             screening) or renal function; or history of any psychotic mental illness or clinically&#xD;
             significant psychiatric disorder&#xD;
&#xD;
          -  History of carpal tunnel syndrome with signs or symptoms within one year before&#xD;
             screening or a Boston Carpal Tunnel Questionnaire score &gt;3&#xD;
&#xD;
          -  Moderate or severe carpal tunnel syndrome based on the 4th finger neurological test or&#xD;
             Total Neuropathy Score nurse&#xD;
&#xD;
          -  History of cancer within 5 years before screening, except for appropriately treated&#xD;
             cutaneous basal cell or squamous cell cancers; cervical cancer; and low grade stable&#xD;
             prostate cancer&#xD;
&#xD;
          -  History, diagnosis, or signs of neurological disease including but not limited to:&#xD;
             stroke; peripheral or autonomic neuropathy; diabetic neuropathy; multiple sclerosis;&#xD;
             epilepsy or seizure disorder with history of seizure within last 2 years; myopathy;&#xD;
             Alzheimer's disease or other types of dementia; head trauma within last 2 years; and&#xD;
             episodic lower limb radiculopathy, nerve compression, or sciatica (provided diagnosed&#xD;
             as due to nerve root compression and not as a manifestation of systemic neuropathy or&#xD;
             radiculopathy)&#xD;
&#xD;
          -  Survey of Autonomic Symptoms score of at least 3&#xD;
&#xD;
          -  Uncontrolled type 1 diabetes or type 2 diabetes with HbA1c &lt;7.5% (type 1 diabetics and&#xD;
             type 2 diabetics that have been controlled by acceptable medication for at least three&#xD;
             months prior to screening are permitted if HbA1c &lt; 7.5%).&#xD;
&#xD;
          -  History or signs and symptoms of coronary heart disease or stroke&#xD;
&#xD;
          -  QTcF interval &lt;330 msec or ≥430 msec for males, and ≥450 msec for females at the&#xD;
             screening examination, unless judged not clinically significant by an investigator&#xD;
&#xD;
          -  Presence of Chronic Obstructive Pulmonary Disease&#xD;
&#xD;
          -  Moderate / severe depression indicated by a score of ≥10 out of 24 in the Personal&#xD;
             Health Questionnaire Depression Scale&#xD;
&#xD;
          -  History or presence of severe adverse reaction to any drug or a history of sensitivity&#xD;
             to mannitol or histidine&#xD;
&#xD;
          -  Use of prescription medicine (other than the permitted medicines) during 28 days&#xD;
             before the dose of trial medication (14 days for pain medication for osteoarthritis&#xD;
             patients)&#xD;
&#xD;
          -  Use of an over-the-counter medicine, except paracetamol, during the 7 days before the&#xD;
             first dose of trial medication&#xD;
&#xD;
          -  Dosed in another clinical trial of a new chemical entity or prescription medicine&#xD;
             within last 3 months&#xD;
&#xD;
          -  Previous use of any Tropomyosin-receptor kinase (TrkA) inhibitor, Nerve Growth&#xD;
             Factor-targeted therapy (eg tanezumab), or experimental biological treatment in last 6&#xD;
             months. More than 6 doses of anti- nerve growth factor (NGF) antibody during&#xD;
             participation in a trial is not permitted.&#xD;
&#xD;
          -  History / presence of drug / alcohol abuse in year before screening, or intake of &gt;28&#xD;
             units of alcohol weekly or currently smoking &gt;10 cigarettes daily&#xD;
&#xD;
          -  Evidence of drug abuse&#xD;
&#xD;
          -  Uncontrolled hypertension (supine) at screening outside 90-140 mm Hg systolic, 40-90&#xD;
             mm Hg diastolic; heart rate in supine position at screening outside 40-100 beats/min.&#xD;
             (Diagnosed hypertension that has been controlled within the above limits using&#xD;
             acceptable medication for at least 3 months prior to screening is permitted.)&#xD;
&#xD;
          -  Possibility that will not cooperate with requirements of the trial&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C or Human Immunodeficiency Virus&#xD;
&#xD;
          -  Loss of more than 400mL blood during last 3 months, eg as a blood donor&#xD;
&#xD;
          -  Objection by General Practitioner to trial entry&#xD;
&#xD;
          -  Poor venous access&#xD;
&#xD;
        Also for osteoarthritis patients:&#xD;
&#xD;
          -  History of inflammatory arthritis, including rheumatoid arthritis, seronegative&#xD;
             spondyloarthropathy (eg ankylosing spondylitis, psoriatic arthritis, inflammatory&#xD;
             bowel disease related arthropathy), gout, pseudogout in index knee (as diagnosed by&#xD;
             appropriate crystals on aspiration or C-reactive protein elevation during attacks&#xD;
             (subjects with gout or pseudogout in a joint other than the index knee must have&#xD;
             disease that is controlled by medication, with a serum uric acid within the target&#xD;
             range; should their index knee flare up during the study, gout must be excluded),&#xD;
             metabolic joint disease, endocrinopathy, lupus erythematosus, joint infection,&#xD;
             connective tissue disease, septic arthritis&#xD;
&#xD;
          -  Radiographic evidence of:&#xD;
&#xD;
               -  excessive malalignment of the knee&#xD;
&#xD;
               -  severe chondrocalcinosis or other arthropathies (eg rheumatoid arthritis)&#xD;
&#xD;
               -  systemic metabolic bone disease (eg pseudogout, Paget's disease, metastatic&#xD;
                  calcifications)&#xD;
&#xD;
               -  large cystic lesions, primary or metastatic tumour lesions&#xD;
&#xD;
               -  acute or healing stress or traumatic fracture (subjects with established united/&#xD;
                  malunited intra or extra-articular fractures of the knee from historic injuries&#xD;
                  [&gt;12 months prior to screening] who have developed features of post-traumatic&#xD;
                  osteoarthritis can be included in the trial, provided that clinically and&#xD;
                  radiologically there is no excessive malalignment of the knee)&#xD;
&#xD;
               -  Rapidly Progressive Osteoarthritis, or any condition which would indicate an&#xD;
                  increased risk for developing it&#xD;
&#xD;
               -  atrophic or hypotrophic osteoarthritis&#xD;
&#xD;
               -  subchondral insufficiency fractures&#xD;
&#xD;
               -  spontaneous osteonecrosis of the knee&#xD;
&#xD;
               -  osteonecrosis&#xD;
&#xD;
               -  pathologic fracture&#xD;
&#xD;
          -  History of osteonecrosis / osteoporotic fracture (including minimally traumatic or&#xD;
             atraumatic fracture)&#xD;
&#xD;
          -  History of significant trauma (including sports injury) or surgery to a knee, hip or&#xD;
             shoulder within last year&#xD;
&#xD;
          -  Planned surgery to a knee, hip or shoulder during the study&#xD;
&#xD;
          -  Fibromyalgia, regional pain caused by lumbar / cervical compression with&#xD;
             radiculopathy, or other moderate/severe pain that may confound assessment of knee pain&#xD;
&#xD;
          -  Intra-articular injection of corticosteroid in the index knee within 3 months, or to&#xD;
             any other joint within 1 month of the initial pain assessment&#xD;
&#xD;
          -  Intra-articular injection of any hyaluronan product in the index knee within 6 months&#xD;
             before the initial pain assessment&#xD;
&#xD;
          -  Any other medical or psychiatric condition, or laboratory abnormality, that may&#xD;
             increase the risk associated with study participation or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the investigator would make&#xD;
             the subject inappropriate for entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denisa Wilkes, MUDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAC Clinical Research - Early Phase Unit</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>healthy</keyword>
  <keyword>volunteer</keyword>
  <keyword>LEVI-04</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

